INmune Bio (INMB) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, will be held virtually, allowing global shareholder participation and voting via webcast.

• Shareholders will vote on electing five directors, ratifying the appointment of CBIZ CPAs P.C. as auditor for 2026, and approving the Third Amended and Restated 2021 Stock Incentive Plan.

• Only holders of record as of April 20, 2026, are entitled to vote; a quorum requires 33.3% of outstanding shares.

Voting matters and shareholder proposals

• Proposals include electing five directors, ratifying CBIZ CPAs P.C. as auditor, and approving the amended 2021 Stock Incentive Plan.

• Board recommends voting FOR all proposals; no dissenters' rights are available.

• Shareholder proposals for the 2027 meeting must be received by December 24, 2026.

Board of directors and corporate governance

• Board consists of five directors with diverse backgrounds in finance, biotech, and clinical research.

• Three standing committees: audit, compensation, and nominating/corporate governance, each with written charters and annual meetings.

• Annual board self-evaluation and code of ethics in place; no family relationships among directors or officers.

• Insider trading and clawback policies are enforced; anti-hedging and pledging restrictions apply.